

Samsung Biologics collaborates with Lilly to establish new gateway labs site in Korea

13 March 2026 | News

Partnership expands Lilly's global network of shared innovation hubs



Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.

The new Gateway Labs site will serve as a hub to support early-stage and emerging biotechnology companies, as they advance scientific research toward development and manufacturing. The facility will feature flexibly designed laboratory space and research infrastructure, collaborative space, and operational support, with capacity for up to 30 companies jointly selected by Lilly and Samsung.

Under the collaboration agreement, Samsung Biologics will develop and operate the new facility, with Lilly Gateway Labs providing customised scientific engagement to support resident biotech companies and catalyse collaboration across the Korea life sciences sector. Located within Samsung Biologics' Bio Campus II site, the facility will comprise five stories totaling 125,000ft² and is expected to be completed in July 2027.

Beyond supporting individual companies, the site is expected to contribute to Korea's broader biotechnology ecosystem by attracting global innovation activity, fostering talent development, and strengthening the country's position as a hub for early-stage life science research. By connecting domestic and international biotech startups with global industry expertise, the initiative aims to accelerate the translation of scientific discovery into development and manufacturing within Korea, supporting long-term growth of the national bio-industry.

The Lilly Gateway Labs model is designed to enable resident companies to accelerate drug discovery and development by combining infrastructure and connecting company founders and scientists with Lilly's global network of experts. Lilly Gateway Labs is part of Lilly Catalyze360, which supports biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities. Since the first Gateway Labs site opened in 2019, resident companies have collectively raised more than \$3 billion, fueling progress on over 50 therapeutic programmes.